Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $372.8 million.

  • ARS Pharmaceuticals' Liabilities and Shareholders Equity rose 71.32% to $372.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 51.58%. This contributed to the annual value of $351.2 million for FY2024, which is 50.59% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $372.8 million for Q3 2025, which was up 18.93% from $313.5 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $382.2 million for Q1 2021, and its period low was $61.4 million during Q4 2021.
  • Over the past 3 years, ARS Pharmaceuticals' median Liabilities and Shareholders Equity value was $258.8 million (recorded in 2023), while the average stood at $276.7 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Liabilities and Shareholders Equity in the last 5 years was 358.02% (2022), contrasted with its biggest fall of 23.12% (2022).
  • Over the past 5 years, ARS Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $61.4 million in 2021, then surged by 358.02% to $281.4 million in 2022, then dropped by 17.14% to $233.2 million in 2023, then skyrocketed by 50.59% to $351.2 million in 2024, then soared by 71.32% to $372.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $372.8 million in Q3 2025, compared to $313.5 million in Q2 2025 and $327.3 million in Q1 2025.